Dyslipidemia Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Alnylam Pharma, Amarin Corp, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Merck

The Key Dyslipidemia Companies in the market include - Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others.

DelveInsight's "Dyslipidemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dyslipidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dyslipidemia Market Forecast [https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dyslipidemia Market Report:

*
The Dyslipidemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In July 2024, NewAmsterdam Pharma reported positive results from the first of its four pivotal Phase III trials, demonstrating that its lead cardiovascular candidate, obicetrapib, effectively lowers cholesterol levels. The BROOKLYN trial (NCT05425745) is the initial study in NewAmsterdam's portfolio, focused on assessing obicetrapib in adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C remains inadequately managed despite receiving the maximum tolerated lipid-lowering therapy.

*
The most common form of dyslipidemia observed was hypercholesterolemia (total cholesterol level greater than or equal to 5.0 mmol/L), with an average prevalence of 58.2%, ranging from 50% to 67% based on the region.

*
The standardized prevalence figures for dyslipidemia in Switzerland, characterized by either self-reported drug use alone or a combination of self-reported drug use and a self-reported diagnosis of dyslipidemia, were 3.7% (95% CI 3.3-4.1%) and 12.2% (95% CI 11.5-12.9%) for women, and 6.3% (95% CI 5.7-6.8%) and 16.9% (95% CI 16.0-17.8%) for men, respectively.

*
Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others

*
Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others

*
The Dyslipidemia epidemiology based on gender analyzed that females are affected more as compared to males, in case of Dyslipidemia

*
The Dyslipidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dyslipidemia pipeline products will significantly revolutionize the Dyslipidemia market dynamics.

Dyslipidemia Overview

Dyslipidemia is a medical condition characterized by abnormal levels of lipids (fats) in the blood. These abnormalities can include elevated levels of low-density lipoprotein cholesterol (LDL-C, often referred to as "bad" cholesterol), triglycerides, and total cholesterol, as well as low levels of high-density lipoprotein cholesterol (HDL-C, known as "good" cholesterol). Dyslipidemia is a major risk factor for cardiovascular diseases, including coronary artery disease and stroke.

Get a Free sample for the Dyslipidemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dyslipidemia-market [https://www.delveinsight.com/report-store/dyslipidemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dyslipidemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dyslipidemia Epidemiology Segmentation:

The Dyslipidemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Dyslipidemia

*
Prevalent Cases of Dyslipidemia by severity

*
Gender-specific Prevalence of Dyslipidemia

*
Diagnosed Cases of Episodic and Chronic Dyslipidemia

Download the report to understand which factors are driving Dyslipidemia epidemiology trends @ Dyslipidemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dyslipidemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dyslipidemia market or expected to get launched during the study period. The analysis covers Dyslipidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dyslipidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dyslipidemia Therapies and Key Companies

*
Pemafibrate (K-877): Kowa Company

*
AZD8233: AstraZeneca And Parexel

*
Rosuvastatin: AstraZeneca

*
GW856553: GlaxoSmithKline

*
A3309: Albireo

*
TA-8995: Xention Ltd

*
Alirocumab: Sanofi

*
Muraglitazar: Bristol-Myers Squibb

*
Atorvastatin (Lipilou): Chong Kun Dang Pharmaceutical

*
MK1903: Merck Sharp & Dohme LLC

*
Lapaquistat acetate: Takeda

*
PPAR alpha: Eli Lilly and Company

Discover more about therapies set to grab major Dyslipidemia market share @ Dyslipidemia Treatment Landscape [https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dyslipidemia Market Drivers

*
Increasing global geriatric population

*
Increase in the prevalence of lifestyle related and cardiovascular disorders

Dyslipidemia Market Barriers

*
Significant proportion of treated patients do not reach recommended treatment goal

*
Increase in availability of generic drugs

Scope of the Dyslipidemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dyslipidemia Companies: Merck Group, Pfizer, Sanofi, Alnylam Pharmaceuticals, Amarin Corporation, Amgen, Bristol Myers Squibb, Cipla, CKD Bio Corporation, AstraZeneca, Daewoong Pharmaceutical, Daiichi Sankyo, Inc, Eli Lilly and Company, Esperion, GSK, Jw Pharmaceuticals Limited, Kadmon, a Sanofi Company, Lupin Pharmaceuticalsl, and others, and others

*
Key Dyslipidemia Therapies: Pemafibrate (K-877), AZD8233, Rosuvastatin, GW856553, A3309, TA-8995, Alirocumab, Muraglitazar, Atorvastatin (Lipilou), MK1903, Lapaquistat acetate, PPAR alpha, and others

*
Dyslipidemia Therapeutic Assessment: Dyslipidemia current marketed and Dyslipidemia emerging therapies

*
Dyslipidemia Market Dynamics: Dyslipidemia market drivers and Dyslipidemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dyslipidemia Unmet Needs, KOL's views, Analyst's views, Dyslipidemia Market Access and Reimbursement

To know more about Dyslipidemia companies working in the treatment market, visit @ Dyslipidemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dyslipidemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dyslipidemia Market Report Introduction

2. Executive Summary for Dyslipidemia

3. SWOT analysis of Dyslipidemia

4. Dyslipidemia Patient Share (%) Overview at a Glance

5. Dyslipidemia Market Overview at a Glance

6. Dyslipidemia Disease Background and Overview

7. Dyslipidemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Dyslipidemia

9. Dyslipidemia Current Treatment and Medical Practices

10. Dyslipidemia Unmet Needs

11. Dyslipidemia Emerging Therapies

12. Dyslipidemia Market Outlook

13. Country-Wise Dyslipidemia Market Analysis (2020-2034)

14. Dyslipidemia Market Access and Reimbursement of Therapies

15. Dyslipidemia Market Drivers

16. Dyslipidemia Market Barriers

17. Dyslipidemia Appendix

18. Dyslipidemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dyslipidemia-market-poised-for-significant-growth-from-2024-to-2034-reports-delveinsight-alnylam-pharma-amarin-corp-amgen-bristol-myers-squibb-cipla-ckd-bio-corporation-astrazeneca-merck]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.